TY - JOUR
T1 - Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
AU - Meric-Bernstam, Funda
AU - Sweis, Randy F.
AU - Hodi, F. Stephen
AU - Messersmith, Wells A.
AU - Andtbacka, Robert H.I.
AU - Ingham, Matthew
AU - Lewis, Nancy
AU - Chen, Xinhui
AU - Pelletier, Marc
AU - Chen, Xueying
AU - Wu, Jincheng
AU - McWhirter, Sarah M.
AU - Müller, Thomas
AU - Nair, Nitya
AU - Luke, Jason J.
N1 - Publisher Copyright:
© 2021 American Association for Cancer Research
PY - 2022/2/15
Y1 - 2022/2/15
N2 - Purpose: This phase I study assessed the safety, pharmacokinetics (PKs), and efficacy of MIW815 (ADU-S100), a novel synthetic cyclic dinucleotide that activates the stimulator of IFN genes (STING) pathway, in patients with advanced/metastatic cancers. Patients and Methods: Patients (n = 47) received weekly i.t. injections of MIW815, 50 to 6,400 mg, on a 3-weeks-on/1-week-off schedule. Results: A maximum tolerated dose was not reached. Most common treatment-related adverse events were pyrexia (17%), chills, and injection-site pain (each 15%). MIW815 was rapidly absorbed from the injection site with dose-proportional PK, a rapid terminal plasma half-life (approximately 24 minutes), and high interindividual variability. One patient had a partial response (PR; Merkel cell carcinoma); two patients had unconfirmed PR (parotid cancer, myxofibrosarcoma). Lesion size was stable or decreased in 94% of evaluable, injected lesions. RNA expression and immune infiltration assessments in paired tumor biopsies did not reveal significant on-treatment changes. However, increases in inflammatory cytokines and peripheral blood T-cell clonal expansion suggested systemic immune activation. Conclusions: MIW815 was well tolerated in patients with advanced/metastatic cancers. Clinical activity of single-agent MIW815 was limited in this first-in-human study; however, evidence of systemic immune activation was seen.
AB - Purpose: This phase I study assessed the safety, pharmacokinetics (PKs), and efficacy of MIW815 (ADU-S100), a novel synthetic cyclic dinucleotide that activates the stimulator of IFN genes (STING) pathway, in patients with advanced/metastatic cancers. Patients and Methods: Patients (n = 47) received weekly i.t. injections of MIW815, 50 to 6,400 mg, on a 3-weeks-on/1-week-off schedule. Results: A maximum tolerated dose was not reached. Most common treatment-related adverse events were pyrexia (17%), chills, and injection-site pain (each 15%). MIW815 was rapidly absorbed from the injection site with dose-proportional PK, a rapid terminal plasma half-life (approximately 24 minutes), and high interindividual variability. One patient had a partial response (PR; Merkel cell carcinoma); two patients had unconfirmed PR (parotid cancer, myxofibrosarcoma). Lesion size was stable or decreased in 94% of evaluable, injected lesions. RNA expression and immune infiltration assessments in paired tumor biopsies did not reveal significant on-treatment changes. However, increases in inflammatory cytokines and peripheral blood T-cell clonal expansion suggested systemic immune activation. Conclusions: MIW815 was well tolerated in patients with advanced/metastatic cancers. Clinical activity of single-agent MIW815 was limited in this first-in-human study; however, evidence of systemic immune activation was seen.
UR - http://www.scopus.com/inward/record.url?scp=85124083541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124083541&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-21-1963
DO - 10.1158/1078-0432.CCR-21-1963
M3 - Article
C2 - 34716197
AN - SCOPUS:85124083541
SN - 1078-0432
VL - 28
SP - 677
EP - 688
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -